01/09/2026
Natroceutics Saffron (AffronTM Extract) available 2000 Whanganui. Have a great day everyone :)
https://www.facebook.com/share/p/1ZLxcVPAhm/
Depressive symptoms are a common concern among women aged 50 to 70.
Although ageing itself does not cause it, factors such as menopause can increase the risk of developing depressive symptoms or clinical depression during this stage of life.
SAFFRON (AFFRON®) STUDY
In a randomised, double-blind, placebo-controlled trial, 86 women were allocated in a 1:1 ratio to receive either 28 mg/day of a saffron extract (Affron®) or placebo for 12 weeks.
The primary outcome was the Depression, Anxiety and Stress Scale–21 (DASS-21) depression subscale.
STUDY RESULT
● Compared with placebo, saffron resulted in greater reductions in DASS-21 depression scores (adjusted mean difference: 2.37; 95% CI: 0.23, 4.51; d = 0.48, p = 0.030).
● A clinically meaningful improvement in depressive symptoms (≥7-point reduction) was achieved by 48.8% of participants receiving saffron compared with 25.6% receiving placebo (p = 0.026).
● Saffron was also associated with greater improvements in self-esteem (adjusted mean difference: 1.43; 95% CI: 0.22, 2.64; d = 0.51; p = 0.022) and sleep-related impairment (adjusted mean difference: 2.99; 95% CI: 0.12, 5.86; d = 0.45; p = 0.041).
The conclusion from the study showed that supplementation with a saffron extract (Affron®) for 12 weeks was associated with improvements in depressive symptoms. Improvements were also observed in self-esteem and sleep-related impairment.
Full study: http://bit.ly/4vl9VSy
______
Our Natroceutics Saffron Bioactive exclusively uses the saffron extract Affron®
______
This post summarises published research findings.
Natroceutics Saffron Bioactive is not intended to diagnose, treat, or manage depression or clinical depressive disorders.
If you are experiencing depressive symptoms, please consult a healthcare professional.